Rifabutin is now recommended as first-line treatment for tuberculosis, but rifampicin is more widely used because of its cheaper cost.
Rifabutin is used in the treatment of Mycobacterium avium complex disease, a bacterial infection most commonly encountered in late-stage AIDS patients. Its main usefulness lies in the fact that it has lesser drug interactions than rifampicin; therefore HIV infected patients on HAART are usually given rifabutin for treatment of TB.